Literature DB >> 12399221

Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis.

Edoardo Giannini1, Paolo Borro, Federica Botta, Alessandra Fumagalli, Federica Malfatti, Elena Podestà, Paola Romagnoli, Emanuela Testa, Bruno Chiarbonello, Simone Polegato, Mario Mamone, Roberto Testa.   

Abstract

BACKGROUND: Thrombocytopenia can be found in patients with chronic hepatitis related to hepatitis C virus (HCV). Both hypersplenism and decreased liver production of thrombopoietin (TPO) have been hypothesized as mechanisms responsible for thrombocytopenia. AIMS: To assess the presence of relationships among platelet count, spleen size, TPO serum levels, liver histology, and liver function in a group of patients with HCV-related chronic hepatitis.
METHODS: Platelet count, TPO serum levels, and spleen size were assessed in 25 untreated HCV positive chronic hepatitis patients undergoing liver biopsy. These parameters were correlated to liver histology and liver function as evaluated by means of [(13)C]aminopyrine breath test (ABT).
RESULTS: Both platelet counts (146 +/- 48 vs. 202 +/- 56 x 10(9)/1, P < 0.03) and TPO serum levels (103 +/- 24 vs. 158 +/- 7 1 pg/ml, P < 0.02) were lower among patients with high fibrosis scores as compared to patients with low fibrosis scores. Patients with thrombocytopenia as well as patients with high fibrosis scores had lower ABT results as compared to patients with normal platelet counts and patients with no or mild fibrosis, respectively. TPO serum levels were correlated to platelet count (r(s) = 0.493, P = 0.016), and negatively correlated to fibrosis stage (r(s) = -0.545, P = 0.008). Lastly, low TPO serum levels were associated to a decrease in liver function.
CONCLUSIONS: Our study showed that in patients with chronic hepatitis related to HCV infection serum TPO levels are correlated to liver functional impairment and to the degree of liver fibrosis. Copyright 2002 European Association for the Study of the Liver

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399221     DOI: 10.1016/s0168-8278(02)00274-x

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  29 in total

1.  Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.

Authors:  S Johansson; W Talloen; M Tuefferd; J M Darling; A Scholliers; G Fanning; M W Fried; J Aerssens
Journal:  Aliment Pharmacol Ther       Date:  2015-08-28       Impact factor: 8.171

2.  Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly.

Authors:  Kazuaki Tejima; Ryota Masuzaki; Hitoshi Ikeda; Haruhiko Yoshida; Ryosuke Tateishi; Yosuke Sugioka; Yukio Kume; Tomoko Okano; Tomomi Iwai; Hiroaki Gotoh; Sachiko Katoh; Atsushi Suzuki; Yukako Koike; Yutaka Yatomi; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2010-03-26       Impact factor: 7.527

3.  Characteristics of splenic CD8+ T cell exhaustion in patients with hepatitis C.

Authors:  K Sumida; S Shimoda; S Iwasaka; S Hisamoto; H Kawanaka; T Akahoshi; T Ikegami; K Shirabe; N Shimono; Y Maehara; C Selmi; M E Gershwin; K Akashi
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

4.  Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates.

Authors:  Erik I Tucker; Ulla M Marzec; Michelle A Berny; Sawan Hurst; Stuart Bunting; Owen J T McCarty; András Gruber; Stephen R Hanson
Journal:  Sci Transl Med       Date:  2010-06-23       Impact factor: 17.956

5.  Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients.

Authors:  Diana V Stefanova-Petrova; Anelia H Tzvetanska; Elisaveta J Naumova; Anastasia P Mihailova; Evgenii A Hadjiev; Rumiana P Dikova; Mircho I Vukov; Konstantin G Tchernev
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

6.  Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma.

Authors:  Satoru Hagiwara; Masatoshi Kudo; Toshihiko Kawasaki; Miki Nagashima; Yasunori Minami; Hobyung Chung; Toyokazu Fukunaga; Masayuki Kitano; Tatsuya Nakatani
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

7.  Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response.

Authors:  Kwong-Ming Kee; Jing-Houng Wang; Chao-Hung Hung; Chien-Hung Chen; Chuan-Mo Lee; Sheng-Nan Lu
Journal:  Dig Dis Sci       Date:  2012-09-22       Impact factor: 3.199

Review 8.  Thrombin activation and liver inflammation in advanced hepatitis C virus infection.

Authors:  Emilio González-Reimers; Geraldine Quintero-Platt; Candelaria Martín-González; Onán Pérez-Hernández; Lucía Romero-Acevedo; Francisco Santolaria-Fernández
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

9.  Impact of Helicobacter pylori eradication on refractory thrombocytopenia in patients with chronic HCV awaiting antiviral therapy.

Authors:  A S Hanafy; A T El Hawary; E F Hamed; A M Hassaneen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-14       Impact factor: 3.267

10.  Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy.

Authors:  Kristen M Marks; Robin M A Clarke; James B Bussel; Andrew H Talal; Marshall J Glesby
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.